Last $21.98 USD
Change Today -0.56 / -2.48%
Volume 2.2M
SRPT On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 8:10 PM 07/11/14 All times are local (Market data is delayed by at least 15 minutes).

Executive Profile*

Christopher Nishan Garabedian

Chief Executive Officer, President and Director, Sarepta Therapeutics, Inc.
AgeTotal Calculated CompensationThis person is connected to 6 board members in 1 different organizations across 1 different industries.

See Board Relationships
47$9,701,492
As of Fiscal Year 2013

Background*

Mr. Christopher Nishan Garabedian, also known as Chris, has been the Chief Executive Officer and President of Sarepta Therapeutics, Inc. (alternatively AVI Biopharma Inc) since January 1, 2011. Mr. Garabedian served as Vice President of Corporate Strategy at Celgene Corporation since July 2007. From November 2005 to June 2007, he served as an Independent Consultant to early-stage biopharmaceutical companies. From 1997 to November 2005, he served at Gilead Sciences, Inc., ...

Read Full Background

Corporate Headquarters*

215 First Street
Cambridge, Massachusetts 02142

United States

Phone: 857-242-3700
Fax: --

Board Members Memberships*

2010-Present
Chief Executive Officer, President and Director

Education*

BS
University of Maryland

Other Affiliations*

Annual Compensation*

Salary$580,000
Total Annual Compensation$580,000

Stock Options*

All Other Compensation$182,022
Exercisable Options348,196
Exercisable Options Value$3,052,147
Unexercisable Options457,637
Unexercisable Options Value$2,707,129
Total Value of Options$5,759,275
Total Number of Options990,833

Total Compensation*

Total Annual Cash Compensation$1,124,522
Total Short Term Compensation$580,000
Other Long Term Compensation$182,022
Total Calculated Compensation$9,701,492
*Data is at least as current as the most recent Definitive Proxy.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SRPT:US $21.98 USD -0.56

COMPETITOR COMPENSATION

NamePosition/
Company
Compensation
John C. Martin Ph.D.Chairman and Chief Executive Officer
Gilead Sciences Inc.
$1.6M
William A. Carter M.D.Chairman, Chief Executive Officer, President, Chief Scientific Officer, Chairman of Executive Committee, Member of Strategic Planning Committee and Member of Disclosure Controls Committee
Hemispherx Biopharma, Inc.
$1.0M
Robert L. Parkinson Jr.Chairman, Chief Executive Officer and President
Baxter International Inc.
$1.5M
Friedhelm Blobel Ph.D.Chief Executive Officer, President, Executive Director and Member of Business Development Committee
SciClone Pharmaceuticals, Inc.
$550.0K
Pascal Soriot Chief Executive Officer, Executive Director and Member of Disclosure Committee
AstraZeneca PLC
3.0M GBP
Compensation as of Fiscal Year 2013.

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SAREPTA THERAPEUTICS INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.